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Articles

Global burden of respiratory infections associated with
seasonal influenza in children under 5 years in 2018:
a systematic review and modelling study
Xin Wang, You Li, Katherine L O’Brien, Shabir A Madhi, Marc-Alain Widdowson, Peter Byass, Saad B Omer, Qalab Abbas*, Asad Ali*,
Alberta Amu*, Eduardo Azziz-Baumgartner*, Quique Bassat*, W Abdullah Brooks*, Sandra S Chaves*, Alexandria Chung*, Cheryl Cohen*,
Marcela Echavarria*, Rodrigo A Fasce*, Angela Gentile*, Aubree Gordon*, Michelle Groome*, Terho Heikkinen*, Siddhivinayak Hirve*,
Jorge H Jara*, Mark A Katz*, Najwa Khuri-Bulos*, Anand Krishnan*, Oscar de Leon*, Marilla G Lucero*, John P McCracken*, Ainara Mira-Iglesias*,
Jennifer C Moïsi*, Patrick K Munywoki*, Millogo Ourohiré*, Fernando P Polack*, Manveer Rahi*, Zeba A Rasmussen*, Barbara A Rath*,
Samir K Saha*, Eric AF Simões*, Viviana Sotomayor*, Somsak Thamthitiwat*, Florette K Treurnicht*, Marylene Wamukoya*,
Lay-Myint Yoshida*, Heather J Zar*, Harry Campbell, Harish Nair, for the Respiratory Virus Global Epidemiology Network†

Summary

Background Seasonal influenza virus is a common cause of acute lower respiratory infection (ALRI) in young children.
In 2008, we estimated that 20 million influenza-virus-associated ALRI and 1 million influenza-virus-associated severe
ALRI occurred in children under 5 years globally. Despite this substantial burden, only a few low-income and middleincome countries have adopted routine influenza vaccination policies for children and, where present, these have
achieved only low or unknown levels of vaccine uptake. Moreover, the influenza burden might have changed due to
the emergence and circulation of influenza A/H1N1pdm09. We aimed to incorporate new data to update estimates of
the global number of cases, hospital admissions, and mortality from influenza-virus-associated respiratory infections
in children under 5 years in 2018.
Methods We estimated the regional and global burden of influenza-associated respiratory infections in children under
5 years from a systematic review of 100 studies published between Jan 1, 1995, and Dec 31, 2018, and a further
57 high-quality unpublished studies. We adapted the Newcastle-Ottawa Scale to assess the risk of bias. We estimated
incidence and hospitalisation rates of influenza-virus-associated respiratory infections by severity, case ascertainment,
region, and age. We estimated in-hospital deaths from influenza virus ALRI by combining hospital admissions and
in-hospital case-fatality ratios of influenza virus ALRI. We estimated the upper bound of influenza virus-associated
ALRI deaths based on the number of in-hospital deaths, US paediatric influenza-associated death data, and populationbased childhood all-cause pneumonia mortality data in six sites in low-income and lower-middle-income countries.
Findings In 2018, among children under 5 years globally, there were an estimated 109∙5 million influenza virus
episodes (uncertainty range [UR] 63∙1–190∙6), 10∙1 million influenza-virus-associated ALRI cases (6∙8–15∙1);
870 000 influenza-virus-associated ALRI hospital admissions (543 000–1 415 000), 15 300 in-hospital deaths
(5800–43 800), and up to 34 800 (13 200–97 200) overall influenza-virus-associated ALRI deaths. Influenza virus
accounted for 7% of ALRI cases, 5% of ALRI hospital admissions, and 4% of ALRI deaths in children under 5 years.
About 23% of the hospital admissions and 36% of the in-hospital deaths were in infants under 6 months. About
82% of the in-hospital deaths occurred in low-income and lower-middle-income countries.
Interpretation A large proportion of the influenza-associated burden occurs among young infants and in low-income
and lower middle-income countries. Our findings provide new and important evidence for maternal and paediatric
influenza immunisation, and should inform future immunisation policy particularly in low-income and middleincome countries.
Funding WHO; Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction
Acute lower respiratory infections (ALRIs) are one of the
leading causes of morbidity and mortality in children
globally, accounting for 16% of mortality in children
under 5 years in 2015.1 We previously estimated that, in
2015, 138 million ALRI cases, 22 million cases of severe
ALRI, and 0∙9 million ALRI deaths occurred globally.2
www.thelancet.com/lancetgh Vol 8 April 2020

Seasonal influenza virus is an important pathogen
associated with ALRI, detected in 3–7% of ALRI hospital
admissions in children under 5 years.3,4 We previously
estimated that 20 million episodes of influenzavirus-associated ALRI, 1 million episodes of severe
influenza-virus-associated ALRI and 28 000–111 000
influenza-virus-associated ALRI deaths occurred in
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Research in context
Evidence before this study
We previously estimated that in 2008, influenza virus was
associated with 13% of all childhood acute lower respiratory
infections ALRI episodes, and 2–10% of all childhood ALRI
deaths, with 99% of these deaths occurring in developing
countries. Since then, additional studies have estimated
influenza-virus-associated or influenza-virus-attributable
morbidity and mortality burden in children under 5 years
globally using different methods. One systematic review (by the
Global Respiratory Hospitalizations—Influenza Proportion
Positive Working Group) estimated that there were 870 000
(95% CI 610 000–1 237 000) influenza-virus-associated ALRI
hospitalisations in 2012 by applying the percentage of
hospitalised children with ALRI positive for influenza virus to
all-cause ALRI hospitalisations. Another study (by the Global
Seasonal Influenza-associated Mortality Collaborator Network)
estimated that there were 44 888 (95% credible interval
9243–105 690) influenza-virus-associated respiratory deaths in
2015 by use of excess respiratory mortality regression models
on vital deaths records and influenza surveillance data. The
third study (by the Institute for Health Metrics and Evaluation)
estimated that there were about 8 million influenza-virusattributable ALRI cases, 2 200 000 influenza-virus-attributable
ALRI hospitalisations, and 23 400 influenza-virus-attributable
ALRI deaths in children under 5 years in 2017; the mortality
estimate was modelled on all-cause ALRI deaths, the population
attributable fraction for influenza virus in ALRI, and the ratio of
case-fatality between viral ALRI and bacterial ALRI.
Added value of this study
Our review was based on laboratory-confirmed influenza
infection morbidity and mortality data. We incorporated an

children under 5 years in 2008.5 Despite this substantial
burden, only 10% of low-income countries (LICs) and
lower-middle-income countries (LMICs) have adopted
national maternal or child influenza immunisation
policies (13% for pregnant women) and, where present,
most have achieved only low or unknown levels of
vaccine uptake.6-9 Influenza burden might have changed
since we calculated these previous estimates due to the
emergence and circulation of influenza A/H1N1pdm09.
We aimed to incorporate new data to estimate the global
number of cases, hospitalisations, and mortality from
influenza-virus-associated ALRI in children under
5 years in 2018. These updated global burden estimates
should inform the development of influenza immuni
sation policies and resource allocation decisions for
young children.

Methods

Systematic review
We did a systematic review of the influenza-virusassociated disease burden in children under 5 years

increased number of studies (157 studies in total, of which
78% were new data) compared to our previous analysis in
2008. Moreover, 36% of these studies were high quality
unpublished data, and 39% from low-income and lowermiddle income countries. The emergence and circulation of
influenza A/H1N1pdm09 might have impacted the influenza
burden globally. Inclusion of new data enabled us to provide
new evidence in the era with the new influenza virus’
circulation, informing future immunisation policy, especially in
low-income and lower middle-income countries. In this review,
we reported influenza-virus-associated respiratory disease
burden by severity and by World Bank income level for age
groups relevant for vaccine policy decisions. We estimated that
influenza virus was associated with 7% of ALRI cases
(10∙1 million cases [uncertainty range (UR) 6∙8–15∙1]), 5% of
ALRI hospitalisations (870 000 [UR 543 000–1 415 000]), and
4% of ALRI deaths (34 800 [UR 13 200–97 200]) in children
under 5 years. About 23% of hospitalisations and 36% of
in-hospital deaths were in infants younger than 6 months.
About 82% of in-hospital deaths occurred in low-income and
lower-middle income countries.
Implications of all the available evidence
Our updated review reports new influenza-virus-associated
ALRI morbidity and mortality estimates in the era with the
circulation of influenza A/H1N1pdm09. A large proportion of
influenza-associated burden occurs among young infants and
among children in low-income and lower-middle-income
countries. Our findings provide new and important evidence for
maternal and paediatric influenza immunisation, and should
inform future immunisation policy particularly in low-income
and middle-income countries.

(appendix pp 4–6). We updated our previous review by
searching Medline (Ovid), Embase (Ovid), Global
Health (Ovid), CINAHL, Web of Science, and the Global
Health Library for studies published between Jan 1, 2009
and Dec 31, 2018; earlier studies published from 1995
onwards in the previous review were also included.5 We
also did our systematic review in three Chinese
databases (CNKI, Wanfang, and Chongqing VIP),
searching for studies published between Jan 1, 1995,
and Dec 31, 2018. To search the grey literature, we also
did broad searches through Google. No language or
publication restrictions were applied, and reviewers
screened the titles and abstracts for eligibility, and
extracted data independently. Articles in non-Chinese or
non-English were translated into English using Google
Translate. Four reviewers (XW, YL, MR, and AC)
screened the English-language databases. Two reviewers
(XW and YL) screened the Chinese-language databases.
Disagreements were resolved by HN.
We included studies that were published between
Jan 1, 1995, and Dec 31, 2018, and reported any of
www.thelancet.com/lancetgh Vol 8 April 2020
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the following data in children younger than 5 years:
community incidence rates of respiratory diseases (eg,
influenza-like-illness, ALRI, and more severe infections)
with laboratory-confirmed influenza virus; hospitalisation
rates of ALRI, ALRI with hypoxaemia, or very severe ALRI
with laboratory-confirmed influenza virus; in-hospital
case-fatality ratios (hCFRs) of ALRI with laboratoryconfirmed influenza virus.
Studies had to use a clearly defined case definition for
specimen collection and testing, and studies that
reported incidence and hospitalisation rate data had to
show data for at least one complete calendar year (or at
least one full influenza season if in a temperate region).
We included hCFR data for any length of period.
We excluded studies: without a clear denominator
population at risk (limited to those reporting incidence
and hospitalisation rate data); those in which influenza
was studied as a co-infection rather than the primary
outcome (ie, only including cases tested negative for
other pathogens, or only including cases co-infected with
influenza virus and other pathogens); reporting modelled
burden estimates; studies in which influenza virus
infections were diagnosed based on serology alone (strict
requirement on sampling timing and serial sampling;
poor sensitivity); explicitly stating that they included any
nosocomial infections in the numerator; only including
Global and regional influenza virus
associated-episodes and influenza
virus associated-ALRI cases

Global and regional influenza virus
associated-ALRI hospitalisations

Systematic review of communitybased studies reporting incidence
rates of influenza virus associatedepisodes, and influenza virus
associated-ALRI

Systematic review of hospital-based
studies reporting hospitalisation
rates of influenza virus associatedALRI

Denominator and case number
imputation for missing 0–59 months

Denominator and case number
imputation for missing 0–59 months

Influenza virus associated-episodes
and -ALRI incidence rate metaestimates by region

Influenza virus associated-ALRI
hospitalisation rate meta-estimates
by age and region

population subgroups with high-risk conditions; or
reporting data from the pandemic period (2009–10
season in temperate regions and the year of 2009 in
tropical regions), or reporting combined data for the nonpandemic and pandemic periods.

Identification and assembly of high-quality unpublished
data
The Respiratory Virus Global Epidemiology Network is a
collaboration network including more than 70 investigator
groups working on respiratory viral infections (eg,
respiratory syncytial virus and influenza virus) and
provided additional unpublished data to supplement
the systematic review.10 We formulated common case
definitions and shared data through agreed common
approaches to data analysis. Other investigators with
relevant data were also invited to contribute data and
participate in the analysis.

Definitions
A study was defined as a dataset from one site in
one published paper or from one research group in the
collaboration network. Similar to our previous analysis,
we used separate case definitions for community-based
studies with active case ascertainment and hospital-based
studies with passive case ascertainment (appendix p 2).10
Global and regional influenza virus associated-ALRI deaths

Systematic review of studies
reporting hCFRs of influenza virus
associated-ALRI

Population-based pneumonia
mortality data

Meta-estimates of hCFRs for
influenza virus associated-ALRI by
age and region

Inflation factor in developing and
industrialised countries

Population estimates

Influenza virus associated-episodes
and -ALRI cases by region

Hospitalisations of influenza virus
associated-ALRI by age and region

Influenza virus associated-ALRI
in-hospital deaths by age and region

Global influenza virus associatedepisodes and -ALRI cases

Global hospitalisations of influenza
virus associated-ALRI

Global influenza virus associatedALRI in-hospital deaths

Global overall influenza virus
associated-ALRI deaths

Figure 1: Approaches for estimation of global influenza virus morbidity and mortality in children under 5 years
We report the number of influenza virus episodes and the number of cases of influenza-virus-associated ALRIs, global influenza-virus-associated-ALRI hospitalisations,
and global estimates of influenza-virus-associated ALRI deaths in hospital and overall deaths (in community). This figure summarises our approach for each outcome and
also shows how they relate to each other. Global estimates of hospitalisations for influenza virus ALRI were estimated by applying hospitalisation rates to population
estimates (2018). Influenza-virus-associated ALRI in-hospital deaths were estimated by combining in-hospital case fatality ratios (hCFRs) for cases and hospitalisations.
The inflation factor was estimated using three approaches (appendix pp 20–26), and we determined to use the most conservative estimate to calculate the number of
overall deaths (appendix pp 20–26). A detailed description of imputation is in the appendix (p 28). ALRI=d acute lower respiratory infection.
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Assessment of risk of biases
13 123 records identified through database search

530 records identified through other sources

5286 duplicates removed

8367 records screened

7234 records excluded as not relevant to topic

We adapted the Newcastle-Ottawa Scale to assess the risk
of bias in included studies.12 The modified scale contains
seven domains: study design, adjustment for health
utilisation, patient groups excluded, case definition,
sampling strategy (ie, how cases were selected for sample
collection and testing), diagnostic testing, and
hypoxaemia ascertainment (appendix pp 9–10). Critical
assessments on the risk of bias (high or low) were made
separately for each domain.

Statistical analysis
1133 full-text papers assessed for eligibility

1044 full-text papers excluded
151 related to 2009 influenza pandemic
5 conference abstracts
102 duplicate data
10 no rate for full influenza seasons or
for complete calendar years
26 no denominator
43 reporting modelled estimates
707 without relevant data for 0–59 months

89 papers included (100 studies)

57 studies from RSV GEN

Studies with incidence rates

Studies with hospitalisation rates

27 IFV-episodes
12 IFV-ALRI
14 IFV-severe ALRI
4 IFV-very severe ALRI

96 IFV-ALRI
17 IFV-ALRI with hypoxaemia
31 IFV-very severe ALRI

66 studies reported in-hospital
case fatality ratios (hCFRs)

Figure 2: Flow diagram for selection of studies on seasonal influenza
For multisite papers, the site-specific data were extracted where available and were analysed as one study; in this
way 100 studies were extracted from 89 papers. One study could provide data on multiple outcomes among
the same population; therefore the total number of studies was greater than the sum of studies by outcomes.
RSV GEN=Respiratory Virus Global Epidemiology Network. IFV=influenza virus. ALRI=acute lower respiratory
infection.
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For community-based studies, the 2005 WHO Integrated
Management of Childhood Illnesses case definition11 for
clinical pneumonia was used to define ALRI since these
definitions were used in most included community
studies and have been widely used as indications for
the treatment of pneumonia. Two further severity levels
for community-based studies included severe ALRI
(ie, ALRI with chest wall indrawing) and very severe ALRI
(ie, ALRI with any general danger signs).11 For hospitalbased studies, where diagnoses were based on physicians’
clinical judgment, we defined hospitalised ALRI as
the physician-confirmed diagnosis of ALRI where
hospitalisation was required or recommended. We
defined two further severity levels: ALRI with hypoxaemia
(SpO2 <90%), and very severe ALRI (ie, children
hospitalised with ALRI with any general danger signs,11
admitted to intensive care units [ICUs], or requiring
mechanical ventilation).

We extracted the number of cases and scaled the
population-at-risk for the proportion of eligible patients
who were tested per study where available (appendix
p 27). We did stratified analyses by case ascertainment,
severity, developing status according to UNICEF
definitions, World Bank income level (LICs, LMICs,
upper-middle-income [UMICs],
and high-income
countries [HICs]), and three non-overlapping age bands
(0–5 months, 6–11 months, and 12–59 months).13,14 Due to
the small number of studies in LICs (appendix pp 7–8),
we combined LICs and LMICs (as LMICs) when reporting
burden estimates. We imputed rates for missing
0–59 months using a multiple imputation approach to
allow for the uncertainty in missing data, and imputed
missing population-at-risks according to the population
structure by country income group based on WHO life
tables (appendix pp 28–29).15–17
Figure 1 summarises our approach for burden
estimation. We estimated incidence rates, hospital
admission rates, and hCFRs of influenza virusassociated respiratory infections using a generalised
linear mixed model.18 In our previous analysis, we used a
classic random-effect model. Compared with the
previous model, the current model has an advantage in
analysing studies with few events and does not require
adding a continuity correction in case of zero events.
The meta-estimates of influenza-virus-associated ALRI
hospitalisation rate from the mixed regression model
were similar to those from the classic random-effects
model for most age groups, except for infants under
3 months (appendix pp 62–63). We estimated influenzavirus-associated ALRI cases (severe and very severe) and
hospitalisations as described previously.10 Incidence
rates and hospitalisation rates were applied to the UN
population estimates for 2018.19,20 The burden estimates
and uncertainty ranges (URs) were calculated using
Monte Carlo simulation, with the median value of
10 000 samples simulated from a log-normal distribution
as the point estimate and the 2∙5th and 97∙5th percentiles
as the 95% UR.10 We included all studies in the main
analyses.
Previous evidence suggested that HIV infection21 was an
important risk factor for influenza hospitalisation and
death, and that the receipt of pneumococcal conjugate
vaccine (PCV)22–25 was associated with reduced risk of
www.thelancet.com/lancetgh Vol 8 April 2020
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Figure 3: Location of included studies on influenza-virus-associated acute lower respiratory infection in children younger than 5 years

hospitalisation and death. As sensitivity analyses, we
stratified data to assess how global influenza-virusassociated ALRI hospitalisations and in-hospital deaths
were affected by (1) study bias (eg, a low risk of bias in
sampling strategy), (2) low or high PCV coverage setting
(≤60% or >60% in general population), and (3) low or high
maternal HIV burden setting (according to the UNAIDS
Global Plan; appendix pp 11–17).26,27 We considered
maternal HIV burden a good proxy of HIV burden in
young children because mother-to-child transmission
of HIV accounted for most HIV infection in young
children.28 Results of sensitivity analyses are in the
appendix (pp 11–19; 22–24). We also reported estimates for
2015 to enable comparisons with the 2015 estimates of
respiratory syncytial virus ALRI burden (appendix, p 19).
We estimated in-hospital deaths by combining
the influenza-virus-associated ALRI hospitalisations
and hCFR meta-estimates as described previously.10
We included all studies in the main analysis of
influenza-virus-associated ALRI in-hospital deaths, and
conducted the same sensitivity analyses as described
above for influenza-virus-associated ALRI hospitalisations
(appendix pp 12–13, 16–17). For overall influenza-virusassociated ALRI mortality analysis, we invited investigators
from the International Network for the Demographic
Evaluation of Populations and their Health (INDEPTH)
Network who had health and demographic surveillance
data for defined populations to provide the numbers of
pneumonia deaths occurring in and out of hospital.29 We
identified six sites (in Mozambique, Kenya, South Africa,
Burkina Faso, and Ghana) with eligible data (appendix
p 20). For industrialised countries, the US InfluenzaAssociated Pediatric Mortality Surveillance System reports
the most relevant data to our knowledge: location-specific
deaths for children under 18 years with laboratoryconfirmed influenza virus infection.30 For our analysis, we
extracted the number of influenza-virus-associated
www.thelancet.com/lancetgh Vol 8 April 2020

paediatric deaths occurring in communities, emergency
departments, and hospitals over 14 years during 2004–18
(excluding the pandemic year of 2009–10). Locationspecific data on deaths among children aged 0–4 years
were unavailable. We assumed health-care access in the
USA was similar to other industrialised countries.
We estimated overall influenza-virus-associated
ALRI deaths by combining in-hospital deaths and the
median inflation factor of overall influenza-virusassociated ALRI deaths versus in-hospital deaths.10,31 For
industrialised countries we calculated the inflation factor
directly by dividing the total number of paediatric
influenza-virus-associated deaths by the number of
deaths occurring in hospitals in the USA.30 For
developing countries where the number of influenzavirus-specific deaths by location was unavailable, we
divided the total number of pneu
monia deaths by
in-hospital pneumonia deaths, and used the median
value across countries to represent the inflation factor
for influenza-virus-specific ALRI deaths. Using this
approach, we assumed that the relative contribution of
influenza to ALRI deaths was the same for hospital and
community settings. In sensitivity analyses we used two
alternative approaches (approaches 2 and 3 in appendix
pp 20–26). Approach 2 and 3 shared the same strategy in
applying the proportion of influenza-virus-associated
ALRI deaths among all-cause ALRI deaths to national
all-cause pneumonia deaths, then dividing the national
number of influenza-virus-associated ALRI in-hospital
deaths, to back-calculate the inflation factor.
All analyses were done in R version 3.5.2, specifically
the metafor package.32,33 This study was done and
reported in accordance with the Guidelines for Accurate
and Transparent Health Estimates Reporting (GATHER)
recommendations and the Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE)
statement (appendix pp 72–74).34,35
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Role of the funding source
The funders of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report. XW and HN (the corresponding author) had
full access to all the data in the study and HN had final
responsibility for the decision to submit for publication.

Results
During 1995–2018, we identified 157 studies (123 new
studies) providing data on community incidence,
hospitalisation rates, and hCFRs (figure 2). Of these
studies, 57 were unpublished and 100 were from
published literature (89 papers). 106 studies (68%) were
from developing countries; 14 studies (9%) were from
LICs, 48 (31%) from LMICs, 29 (18%) from UMICs,

LMICs

UMICs

HICs

62 (39%) from HICs, and four studies from multiple
countries from different country income groups
(appendix pp 7–8; 30–58). Figure 3 shows where the
included studies were conducted.
38 community-based studies reported incidence.
27 studies reported incidence of influenza virus episodes
for 0–59 months, and 12 studies reported incidence
for influenza-virus-associated ALRI cases (appendix
pp 30–32). In 2018 among children under 5 years, we
estimated 109∙5 million (UR 63∙1–190∙6) influenza virus
episodes and 10∙1 million (UR 6∙8–15∙1) influenza-virusassociated ALRI cases globally. We were unable to
estimate the burden in UMICs due to the scarcity of
studies. We estimated 1∙4 million (UR 0∙6–3∙4) severe
influenza-virus-associated ALRI cases, and 0∙4 million

Developing countries

Industrialised
countries

Global burden estimates*

Influenza virus episodes
Age 0–5 months
Studies
Incidence (per 1000 children per
year)†
Episodes (1000s)

9
80·2 (40·9–151·6)
3552 (1848–6831)

1

0

10

··

··

··

··

80·8 (44·2–143·1)

··

··

··

··

··

··

5018 (2792–9023)

Age 6–11 months
Studies
Incidence (per 1000 children per year)
Episodes (1000s)

1

0

··

··

165·9 (93·2–277·8)

2

··

··

164·8 (92·6–276·2)

2

··

··

7233 (4201–12 457)

··

··

10 162 (5902–17 502)

··

··

3

··

Age 12–59 months
Studies
Incidence (per 1000 children per year)
Episodes (1000s)

2

1

3

138·6 (57·2–299·4)

··

147·3 (82·6–248·9)

47 524 (20 871–108 280)

··

7467 (4315–12 926)

2
138·6 (57·2–299·4)
67 125 (29 479–152 938)

147·3 (82·6–248·9)
8199 (4738–14 194)

··
74 448 (33 844–165 089)

Age 0–59 months
Studies
Incidence (per 1000 children per year)
Episodes (1000s)

8 (3)‡

1

175·2 (101·5–302·3)

··

75 538 (43 911–129 996)

··

9 (3)
61·9 (32·5–117·9)
3925 (2068–7453)

8 (3)
175·2 (101·5–302·3)
106 557 (61 943–183 376)

10 (3)

··

42·4 (17·2–104·8)
2953 (1202–7259)

··
109 510 (63 145–190 635)

Influenza virus-associated ALRI cases
Age 0–5 months
Studies

4

1

0

5

··

··

Incidence (per 1000 children per year)

4·9 (2·2–10·8)

··

··

8·5 (2·6–26·9)

··

··

··

··

528 (165–1688)

··

··

Episodes (1000s)

217 (98–479)

Age 6–11 months
Studies
Incidence (per 1000 children per year)
Episodes (1000s)

1

0

··

··

28 (23·6–33·3)

4

··

··

27·6 (23·4–32·6)

5

··

··

1229 (1036–1459)

··

··

1702 (1444–2008)

··

··

Age 12–59 months
Studies
Incidence (per 1000 children per year)
Episodes (1000s)

1

0

··

··

16·7 (8·6–32·3)

4

··

··

15·6 (8·9–27·1)

5

··

··

5727 (29 66–11 062)

··

··

7556 (4344–13 149)

··

··

4 (3)

··

Age 0–59 months
Studies
Incidence (per 1000 children per year)
Episodes (1000s)

1

4 (3)

14·6 (9·2–23·3)

7 (3)‡

··

9·3 (7·5–11·5)

6299 (3961–10 021)

··

590 (477–729)

8 (3)
15·6 (10·3–23·6)
9498 (6305–14 313)

9·3 (7·5–11·5)
648 (524–800)

··
10 145 (6829–15 113)
(Table 1 continues on next page)
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LMICs

UMICs

HICs

Developing countries

Industrialised
countries

Global burden estimates*

(Continued from previous page)
Severe influenza virus-associated ALRI cases
Age 0–5 months
Studies

11

Incidence (per 1000 children per year)
Episodes (1000s)

4·1 (1·8–9·3)
182 (80–411)

1

0

··

··

··

··

12
5·1 (2·2–11·9)
317 (137–733)

0

··

··

··

··

··

Age 6–11 months
Studies

3

1

0

4

0

··

Incidence (per 1000 children per year)

3·9 (1·4–11·1)

··

··

6·1 (2·2–16·4)

··

··

··

··

376 (139–1021)

··

··

Episodes (1000s)

171 (61–479)

Age 12–59 months
Studies

3

1

0

4

0

··

Incidence (per 1000 children per year)

1·2 (0·6–2·4)

··

··

1·9 (0·7–5·1)

··

··

412 (207–820)

··

··

··

··

Episodes (1000s)

920 (343–2471)

Age 0–59 months
Studies

6 (3)‡

1

0

7 (3)

0

··

Incidence (per 1000 children per year)

1·7 (0·9–3·2)

··

··

2·4 (1–5·6)

··

··

727 (386–1371)

··

··

1438 (612–3384)

··

··

Episodes (1000s)

Very severe influenza virus-associated ALRI cases
Age 0–5 months
Studies

3

1

0

4

0

··

Incidence (per 1000 children per year)

0·1 (0–122·1)

··

··

0·3 (0–13·3)

··

··

Episodes (1000s)

4 (0–673)

··

··

··

··

Studies

3

1

0

4

0

··

Incidence (per 1000 children per year)

0·8 (0·2–4)

··

··

1 (0·3–3·5)

··

··

··

··

62 (18–209)

··

··

19 (0–940)

Age 6–11 months

Episodes (1000s)

35 (8–156)

Age 12–59 months
Studies

2

1

0

3

0

··

Incidence (per 1000 children per year)

0·3 (0–2)

··

··

0·5 (0·1–2·3)

··

··

103 (5–2024)

··

··

242 (51–1152)

··

··

Episodes (1000s)
Age 0–59 months
Studies

3 (1)‡

1

0

4 (1)

0

··

Incidence (per 1000 children per year)

0·5 (0·1–2·8)

··

··

0·7 (0·2–2·7)

··

··

211 (37–1194)

··

··

··

··

Episodes (1000s)

416 (105–1641)

Data in parentheses are estimated uncertainty ranges. Data were imputed using a multiple imputation approach. ALRI=acute lower respiratory infection. LMICs=lower-middle income countries. UMICs=uppermiddle income countries. HICs=high-income countries. ··=not available. *Global burden estimates were developed by summing up estimates for 0–59 months by country development status classified according to
UNICEF definition. †Incidence was estimated using generalised linear mixed models. ‡Data in parentheses are the number of imputed studies.

Table 1: Estimates of the incidence (per 1000 children per year), and number of influenza virus episodes and influenza virus-associated ALRI cases in children under 5 years in the
community in 2018, by World Bank income level and development status

(UR 0∙1–1∙6) very severe influenza-virus-associated
ALRI cases in children under 5 years in developing
countries (table 1).
We identified 96 studies reporting influenza-virusassociated ALRI hospital admission rates, including
59 studies with data on age groups 0–5 months,
6–11 months, or 12–59 months (appendix pp 37–43).
Among children under 5 years, we estimated
870 000 hospital admissions (UR 543 000–1 435 000) for
influenza-virus-associated ALRI globally, of which 23%
and 21% were in infants aged 0–5 months and
6–11 months, respectively (table 2). An estimated
www.thelancet.com/lancetgh Vol 8 April 2020

420 000 hospital admissions for influenza-virusassociated ALRI (UR 261 000–677 000) occurred in
LMICs. In subgroup analyses of studies with low risk of
bias and in analyses stratified by low or high national
PCV coverage and by low or high national maternal HIV
burden, the hospital admission estimates were similar to
those in the main analysis; the point values ranged from
772 000 to 895 000 for hospital admissions, with wide and
overlapping URs (appendix pp 11–15).
For infants under 1 year, incidence meta-estimates of
influenza virus episodes and of influenza-virus-associated
ALRI cases increased with age (p for linear trend <0∙05,
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LMICs

UMICs

HICs

13

9

13

Developing
countries

Industrialised
countries

Global*

Influenza virus–associated ALRI
Age 0–5 months
Studies
Rate (per 1000 children per year)†
Hospital admissions (1000s)

1·8 (1·1–3·1)
80 (48–133)

3·7 (1·8–7·4)
68 (34–138)

4·4 (3·1–6·3)
28 (20–40)

24

11

2·8 (1·8–4·3)
174 (113–268)

3·7 (2·7–5·3)
26 (18–36)

··
··
200 (131–304)

Age 6–11 months
Studies
Rate (per 1000 children per year)
Hospital admissions (1000s)

11
1·5 (1–2·4)

8

9

3·8 (1·7–8·3)

3·5 (1·4–8·8)

66 (43–102)

70 (32–154)

22 (9–55)

17

11

20

21
2·7 (1·7–4·3)
166 (105–264)

7

··

2·6 (0·9–7·6)

··

18 (6–52)

185 (111–317)

Age 12–59 months
Studies
Rate (per 1000 children per year)
Hospital admissions (1000s)

1·2 (0·6–2·2)

35

13

0·9 (0·6–1·5)

0·9 (0·4–1·8)

··

0·8 (0·5–1·3)

0·8 (0·3–2)

··

274 (171–441)

117 (46–301)

61 (32–116)

436 (276–688)

50 (24–106)

486 (300–794)

420 (261–677)

255 (111–593)

111 (60–211)

776 (494–1220)

94 (48–194)

870 (543–1415)

Age 0–59 months
Hospital admissions (1000s)

Influenza virus-associated ALRI with hypoxaemia
Age 0–5 months
Studies

8

2

··

Rate (per 1000 children per year)

0·9 (0·5–1·6)

0·9 (0·5–1·5)

··

Hospital admissions (1000s)

40 (22–71)

17 (10–29)

10
0·9 (0·6–1·4)

··

56 (37–85)
10

··

··

··

··

··

··

Age 6–11 months
Studies

8

2

··

Rate (per 1000 children per year)

0·7 (0·3–1·4)

1 (0·7–1·6)

··

Hospital admissions (1000s)

31 (14–66)

18 (12–28)

··

0·8 (0·5–1·1)
49 (33–73)

··

··

··

··

··

··

Age 12–59 months
Studies

8

1

2

9

2

··

Rate (per 1000 children per year)

0·2 (0·1–0·4)

··

0 (0–1·3)

0·2 (0·1–0·3)

0 (0–1·3)

··

69 (34–137)

··

0 (0–4)

139 (71–274)

··

··

Hospital admissions (1000s)

97 (56–167)

0 (0–4)

97 (56–172)

Age 0–59 months
Hospital admissions (1000s)

202 (126–326)

7 (1–62)‡

209 (127–387)

Very severe influenza virus-associated ALRI
Age 0–5 months
Studies

9

3

2

Rate (per 1000 children per year)

0·6 (0·2–1·4)

0·2 (0·1–0·4)

0·3 (0·1–0·7)

4 (2–7)

2 (1–5)

19 (6–56)
12

Hospital admissions (1000s)

27 (10–70)

12
0·3 (0·1–0·9)

2

··

0·3 (0·1–0·7)

··

2 (1–6)

21 (7–61)

Age 6–11 months
Studies

9

3

2

Rate (per 1000 children per year)

0·5 (0·3–0·9)

0·3 (0·1–1)

0·1 (0–0·6)

6 (2–17)

1 (0–7)

25 (12–49)

8

16

Hospital admissions (1000s)

22 (13–38)

0·4 (0·2–0·8)

2

··

0·1 (0–0·6)

··

1 (0–8)

25 (12–57)

Age 12–59 months
Studies

9

5

Rate (per 1000 children per year)

0·1 (0–0·3)

0·1 (0–0·2)

Hospital admissions (1000s)

<0·05

0·1 (0–0·2)

6

··

<0·05

··

34 (4–263)

15 (2–92)

0 (0–0)

48 (8–303)

0 (0–0)

49 (8–304)

83 (27–371)

24 (6–116)

3 (1–12)

92 (26–408)

3 (1–13)

95 (28–421)

Age 0–59 months
Hospital admissions (1000s)

Data in parentheses are estimated uncertainty ranges. ALRI=acute lower respiratory infection. LMICs=lower-middle income countries. UMICs=upper-middle income countries.
HICs=high-income countries. ··=not available. *Global burden estimates were developed by summing up estimates in three non-overlapping age groups (0–5 months,
6–11 months, and 12–59 months), and in developing and industrialised countries classified according to UNICEF definition. †Hospital admissions rates were estimated using
generalised linear mixed models. ‡In industrialised countries, two studies reported the hospital admission rates for influenza virus-associated ALRI with hypoxaemia for
0–59 months; the meta-estimate was 0∙1 (<0∙05–0∙4), translating to 7000 (UR 1000–62 000) hospital admissions.

Table 2: Estimates of hospital admission rates (per 1000 children per year), and number of hospital admissions in children under 5 years with influenza
virus-associated ALRI in 2018, by World Bank income level and development status
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LMICs
Studies†

10

UMICs
11

HICs

Developing countries

7

23

Industrialised
countries
5

Global*
··

Age 0–5 months
hCFR (%)‡
Deaths

3·2 (0·6–15·4)
2500 (500–13 800)

2·6 (0·9–7·5)
1800 (500–6200)

0·5 (0–4·6)
100 (0–4100)

3·1 (1·3–6·9)
5400 (2100–13 700)

0·3 (0–6·9)
100 (0–2700)

··
5500 (2100–16 300)

Age 6–11 months
hCFR (%)
Deaths

8·1 (4·1–15·3)
5300 (2400–11 600)

0·7 (0·1–7·4)
500 (0–4700)

0·8 (0·2–3·2)
200 (0–900)

2·0 (0·6–6·2)
3300 (900–11 500)

0·9 (0·2–3·4)
200 (0–900)

··
3500 (1000–12 400)

Age 12–59 months
hCFR (%)
Deaths

3·3 (1·7–6·3)
9100 (4000–20 100)

0·8 (0·3–2·2)
900 (200–3700)

0·4 (0·1–2·1)
200 (0–1300)

1·4 (0·7–2·8)
6100 (2700–13 800)

0·4 (0·1–2·7)
200 (0–1200)

··
6300 (2700–14 900)

Age 0–59 months
Deaths

17 000 (6900–45 100)

3200 (800–14 400) 600 (100–6200)

14 800 (5700–39 000)

500 (100–4800)

15 300 (5800–43 800)

Data in parentheses are estimated uncertainty ranges. ALRI=acute lower respiratory infection. LMICs=lower-middle income countries. UMICs=upper-middle income
countries. HICs=high-income countries. ··=not available. *Global estimates were calculated by summing up estimates in three non-overlapping age groups (0–5 months,
6–11 months, and 12–59 months), and in developing and industrialised countries according to UNICEF definitions. †hCFR meta-estimates were based on studies providing
data for the three non-overlapping age bands. ‡hCFRs were estimated using generalised linear mixed models.

Table 3: In-hospital case fatality ratio (hCFR) meta-estimates and in-hospital deaths in children under 5 years with influenza virus-associated ALRI in
2018, by World Bank income level and development status

appendix p 67). The linear trend for hospital admission
rates was not significant. However, the hospital admission
rate of influenza-virus-associated ALRI was lower in
neonates (0∙9 per 1000 neonates per year, 95% CI 0∙4–1∙8),
and was consistently higher in infants older than 1 month
(1∙6–1∙9 per 1000 infants per year) in developing countries.
Only two studies reported hospital admission rates of
influenza-virus-associated ALRI by narrow age groups
among infants in industrialised countries.
Based on 15 studies, we estimated 209 000 hospital
admissions for influenza-virus-associated ALRI with
hypoxaemia (UR 127 000–387 000) globally in children
under 5 years. An estimated 139 000 (UR 71 000–274 000)
hospital admissions occurred in LMICs (table 2). For
very severe influenza-virus-associated ALRI, based on
24 studies, we estimated 95 000 (UR 28 000–421 000)
hospital admissions in children under 5 years globally,
22% and 26% in infants aged 0–5 months and
6–11 months, respectively (table 2). An estimated 83 000
(UR 27 000–371 000) hospital admissions for very severe
influenza-virus-associated ALRI occurred in LMICs.
66 studies reported hCFRs for influenza-virusassociated ALRI in children under 5 years, including
28 studies with data on three non-overlapping age
bands (appendix pp 49–53). We estimated that hCFRs
for influenza-virus-associated ALRI were 3∙1% (95% CI
1∙3–6∙9), 2∙0% (0∙6–6∙2), and 1∙4% (0∙7–2∙8) in
children aged 0–5 months, 6–11 months, and
12–59 months in developing countries, respectively
(table 3). By country-income group, hCFRs were higher
in LMICs (3∙4%, 95% CI 1∙4–7∙9, for 0–59 months)
than UMICs (1∙4%, 0∙6–3∙5) and HICs (0∙5%, 0∙2–1∙4).
The analysis stratified by age and country develop
ment status yielded 15 300 influenza-virus-associated
ALRI (UR 5800–43 800) in-hospital deaths in children
www.thelancet.com/lancetgh Vol 8 April 2020

under 5 years, with 36% and 23% among infants aged
0–5 months and 6–11 months, respectively. About
82% of influenza-virus-associated ALRI in-hospital
deaths occurred in LMICs. We did stratified analyses in
studies with low risk of bias, by low or high national
PCV coverage and by low or high maternal HIV burden.
In these sensitivity analyses, in-hospital mortality
estimates were similar to those in the main analysis; the
point values ranged from 13 800 to 20 800 for in-hospital
mortality, with wide and overlapping URs (appendix
pp 12–13, 16–17).
For industrialised countries, we estimated an inflation
factor of 1∙6 (range 1∙3–1∙9 across 14 years) based on the
data for US paediatric influenza-virus-associated deaths.
For developing countries, we used an inflation factor of
2∙3 in the main analysis (range 1∙5–3∙5 across six sites),
and estimated an overall influenza-virus-associated ALRI
mortality of 34 800 (UR 13 200–97 200) in children under
5 years globally. In sensitivity analyses, we estimated a
higher inflation factor in approach 2 (3∙0) and
approach 3 (3∙4). Using the two approaches, the point
overall mortality estimate could increase by 30–47%, with
wide and overlapping URs (appendix pp 20–26).

Discussion
We estimated that globally in 2018, in children under
5 years, there were 109∙5 million influenza virus
episodes, around 10 million cases of influenza-virusassociated ALRI, about 870 000 hospital admissions
for influenza-virus-associated ALRI, 15 000 in-hospital
deaths from influenza-virus-associated ALRI, and around
35 000 total deaths from influenza-virus-associated ALRI.
The wide uncertainty ranges of the burden estimates
reflected differences across studies, arising from the
variation in influenza activity between seasons, variation
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in influenza epidemiology between populations and
methodological differences, and lack of data, especially
mortality data.
The incidence rates of influenza virus episodes and
influenza-virus-associated severe ALRI in children under
5 years were consistent with our previous estimates
for 2008.5 However, we estimated a lower incidence
of influenza-virus-associated ALRI compared with the
previous review for 0–59 months in developing countries.
In the previous review, the incidence of influenzavirus-associated ALRI was only based on three studies
from two sites. Our updated estimate was refined by
incorporating new data with larger sample sizes achieved
by multiple-season observation and data from more
geographically diverse areas (12 studies). Improved
influenza vaccine uptake is not likely to be the reason for
the lower incidence of influenza-virus-associated ALRI
since paediatric influenza immunisation policy had not
been introduced (in Bangladesh, India, and Pakistan), or
was only introduced in children with chronic diseases (in
Nicaragua), or achieved low coverage (in South Africa)
during the study periods.36 The national PCV coverage
was above 60% midway in three studies in Nicaragua,
Pakistan, and South Africa; increase in PCV uptake
might contribute to the lower point value of incidence
rates.26,37 The reduction in influenza-virus-associated
ALRI incidence rates is consistent with a general decrease
in the incidence of all-cause ALRI.2 Our estimate of
influenza-virus-associated ALRI cases, after accounting
for the attributable fraction of influenza virus in
influenza-virus-associated ALRI (80%), generally agreed
with the number of influenza-virus-attributable ALRI
cases (about 8 million) estimated by the Institute for
Health Metrics and Evaluation (IHME).
We estimated about 870 000 influenza-virus-associated
ALRI hospitalisations (about 5% of all-cause hospitalised
ALRI), similar to our previous estimate.5,38 Our estimate
developed using an incidence-based approach, is lower
than the IHME estimate of influenza-virus-attributable
ALRI hospitalisations for 2017 (about 2 200 000) derived
from a proportion-based approach.39 The difference in the
two estimates might reflect the difference in analytical
methods; data used in the two analytical methods were
not directly comparable. Nevertheless, a previous study
reported an estimate similar to our result, although using
a proportion-based approach.4 Our global estimates for
influenza-virus-associated ALRI hospitalisations changed
marginally (if at all) in sensitivity analyses, suggesting
that they were not affected by study biases, or inclusion of
data from different settings—eg, with different PCV
coverages and HIV burden. The primary objective of
doing these sensitivity analyses was to assess to what
extent the global estimates would be affected by these
factors. It is important to note that the estimates in the
stratified analyses by PCV coverage (and by 2009) were
not directly comparable because most data were from
different areas. We identified five studies reporting
e506

influenza-virus-associated ALRI hospitalisation rates for
at least 5 consecutive years with PCV introduced midway.
In a pooled regression analysis of the five studies, we did
not find a significant difference in influenza-virusassociated ALRI hospitalisation rates between high PCV
coverage periods and low coverage periods. However, this
finding needs to be interpreted with caution because the
five studies had short observation periods (5–8 years). In
the main analyses of influenza-virus-associated ALRI
hospitalisations, most studies were from the post-2009
period, and hospitalisation estimates did not change after
excluding pre-2009 data. Moreover, the estimate did not
change after excluding 2010 data, when the influenza
pandemic affected some regions.40 80% of influenzavirus-associated ALRI can be attributed to influenza
based on a systematic review of case-control studies
investigating the viral profile in children under 5 years
with and without ALRI. Thus, based on our estimate,
696 000 ALRI hospitalisations could be attributed to
influenza virus in children under 5 years.41
We estimated 15 300 influenza-virus-associated ALRI
in-hospital deaths based on 28 hCFR studies. The
estimates were not affected by risk of bias or by the
inclusion of data from different PCV coverage settings
and HIV burden settings. We estimated up to 4% of all
childhood ALRI deaths were associated with influenza
virus.2 Our estimate was between the IHME influenzavirus-attributable ALRI mortality estimate (about
23 400 influenza-virus-attributable ALRI deaths in 2017)
and the influenza-virus-associated respiratory mortality
estimate in a study by Iuliano and colleagues (44 888,
95% credible interval 9243–105 690, in 2015) for
92 countries where 92% of respiratory deaths occurred.39,42
The IHME mortality estimate was modelled on all-cause
ALRI deaths, the percentage of influenza virus in patients
with ALRI from published literature, the attributable
fraction of influenza virus for influenza-virus-confirmed
ALRI, and the ratio of case-fatality between viral ALRI
and bacterial ALRI (viral-to-bacterial case fatality ratio).39
Iuliano and colleagues did a time series analysis using
records for vital respiratory deaths and influenza
circulation data in three countries, and extrapolated these
to other countries. The different estimates in the
two studies reflected the difference in case definitions
(respiratory deaths vs ALRI deaths) and in statistical
models;43 we used three different approaches to model
the number of overall deaths, and reported the most
conservative influenza-virus-associated ALRI mortality
burden.
For calculation of the upper bound of influenza-virusassociated ALRI mortality (overall influenza-virus-associ
ated ALRI mortality), we estimated a more conservative
inflation factor (2∙3) for developing countries in the
main analysis than those used in another two approaches
in sensitivity analyses (3∙0 in approach 2 and 3∙4 in
approach 3). Each approach has potential biases.
One modelling study in South Africa estimated that
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a significantly higher percentage of influenza-virusattributable deaths occurred outside hospitals than the
percentage of all-cause deaths occurring outside hospitals
(57% versus 41%).44 This finding suggests that using the
inflation factor for all-cause pneumonia might under
estimate the influenza-virus-specific estimate in the main
analysis. Potential biases for approaches 2 and 3 are
explained in the appendix, pp 20–24. Although estimated
using data from six sites, the estimated inflation factor
was still limited by lack of data. Health-care access varies
significantly across the world; most data we included
were from rural areas and from LMICs. The inflation
factor and the upper bound of mortality estimate in
developing countries might be overestimated due to the
poor access to health care at these sites. Care-seeking has
been investigated in national household surveys of
11 Middle East and North African countries: 34–80%
(median 70% approximately) of children under 5 years
with acute respiratory infections (caregiver’s self-report)
sought care in health facilities.45 However, it is still
challenging to understand the scenario of ALRI deaths
from these data. For industrialised countries, we
estimated the inflation factor using mortality data for
0–17 years, which might cause an underestimation if
young children are more likely to die before being
admitted, or an overestimation if young children are
more likely to be taken to health-care facilities when they
are sick.46
We estimated the highest hCFRs in LMICs, and 82% of
the in-hospital deaths occurred in these countries.
However, only 10% of LICs and LMICs have had a
national policy for influenza immunisation in children
(13% for pregnant women) in 2014.9 Where present there
were mostly very low or unknown levels of vaccine
coverage.6,47–50 According to previous evidence, a high
influenza vaccine coverage (about 70%) can substantially
reduce influenza-associated hospitalisations and deaths
in children under 5 years of age.51
A large proportion of influenza-virus-associated ALRI
hospitalisations (44%) and in-hospital deaths (59%)
occurred during infancy, with 23% of hospitalisations and
36% of the in-hospital deaths in infants under 6 months.
Our estimates of influenza-virus-associated ALRI hospitali
sations are likely to underestimate the effect of influenza.
Influenza can cause primary infections or expose children
to severe secondary bacterial infections while not being
detected at specimen collection. Maternal influenza
vaccination trials assessing vaccine efficiency against
hospitalised ALRI might help to understand the direct
and indirect effects of influenza in causing ALRI.52,53 The
infant data we included were from developing countries
with either no influenza immuni
sation policy or low
influenza vaccine coverage in pregnant women during the
study periods (ie, Bangladesh, Guatemala, India, Kenya,
Mozambique, South Africa, and Thailand).36,54,55 Findings
from two trials in Mali and South Africa suggested
that maternal influenza immunisation is an effective
www.thelancet.com/lancetgh Vol 8 April 2020

intervention against influenza infections in the first
3 months of age.56,57 Influenza virus predisposes individuals
to secondary bacterial infection and adverse outcomes
associated with such infections.58 Therefore, preventing
influenza virus through maternal immuni
sation could
play a role in reducing the burden of all-cause ALRI. For
example, in a pooled analysis of three maternal influenza
immunisation trials in South Africa, Mali, and Nepal,
there was a 20% reduction in all-cause severe clinical
pneumonia in infants under 6 months.53 However, there
was heterogeneity in this effect between three trials;
therefore, it would be challenging to quantify the global
effect of maternal influenza immunisation on reducing
all-cause ALRI in early infancy.
Our burden estimates were generally robust to the
sensitivity analyses we performed. However, there were
some limitations in our review. First, although we pre
specified case definitions, heterogeneity between studies
still existed; for example, 50% of hospital-based
studies used other definitions (eg, hospitalised acute
respiratory infection). This might cause an overestimation
of influenza-virus-associated ALRI hospitalisations.
Second, PCR was used in about 70% of hospital-based
studies to detect influenza, and diagnostic tools with
lower sensitivity were used in 30% of studies. However,
the hospitalisation estimates did not change when
restricting the analysis to these PCR studies. Third, not
all infections were tested for influenza virus. For
incidence and hospitalisation rates, we have adjusted for
underdetection, assuming the proportion of influenza
virus in tested and untested cases was the same. Studies
were systematically assessed, and the rates might have
been biased in some studies: for influenza-virusassociated ALRI hospitalisation rates, at least 90% of
eligible cases were tested in 50% of studies; less than
90% of cases were tested in 30% of studies, and the main
reasons for not collecting specimens included cases being
tested systematically (17%), refusal and discharge (10%),
and unknown reasons (3%); in the remaining 20% of
studies the proportion tested was unavailable. We
reported unadjusted hCFRs, which might be under
estimated because children who were very ill were less
likely to be sampled and tested, as suggested by the higher
hCFRs among untested cases than those tested (appendix
p 26). Fourth, hospitalisation estimates were affected by
access to health care and health-seeking behaviour, so the
potential numbers of influenza-virus-associated ALRI
hospitalisations are likely to be higher in resource-limited
areas and in older children who are less likely to be taken
to health-care facilities when they are sick.46 Furthermore,
influenza vaccine coverage has increased over the last
decade in industrialised countries (eg, in the USA).
Estimates based on data during the low vaccine coverage
period could cause an overestimation. Due to the scarcity
of influenza vaccine coverage data in most countries, we
determined not to adjust influenza vaccine use in
estimating influenza-associated burden.
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Based on 157 studies of which 123 studies were not
included in our 2008 estimates, we reported the new
estimates in the era with the circulation of
influenza A/H1N1pdm09. Although we included more
studies than our previous review, estimates were still
based on limited data. High-quality in-hospital mortality
data, especially from LICs, are needed to improve the
global in-hospital mortality estimate. Studies reporting
age-stratified influenza-virus-associated ALRI morbidity
and mortality burden should be encouraged. Moreover,
further influenza-virus-associated ALRI mortality studies
should ensure optimal sample size for robust mortality
estimation. These efforts will help refine estimates of
global burden of influenza in young children and
understand the role of influenza in childhood disease, and
inform policy. The initiation of post-mortem surveillance
such as in the Child Health and Mortality Prevention
Surveillance Network, will provide evidence to improve
influenza-virus-associated mortality estimation.59
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